| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
The Cooper Companies, Inc.$70.29
-0.02 (-0.03%)
C 49Pipeline Score MedTech · Commercial
Market Cap
12.20 B
EPS
2.03
P/E Ratio
30.96 $
Value Trade
241.13 M
SEC Financials
Q2 2026Dilution Risk
50%Revenue
1.08 B
R&D Expenses
42.50 M
Total Assets
12.48 B
Total Liabilities
4.24 B
Equity
8.24 B
D/E Ratio
12,345
3.37 %
Week
-7.28 %
1 Month
-25.13 %
3 Month
-12.79 %
6 Month
-35.96 %
5 Year
773.72 %
All Time
Cash Data
Cash Position
139.00 M
Monthly Burn
10.33 M
Runway
11.8 mo
Burn Trend
SEC Filing
Jun 5, 2026
Overview
Volume
2.20 M
52 Week Range
58.89 - 89.83
% held by Insiders
0.67 %
% held by Institutions
105.13 %
Enterprise Value
14.58 B
Total Shares
195.17 M
Short %
4.16 %
Float Shares
190.49 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for The Cooper Companies, Inc.
41Total events
1Upcoming
11Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 1
TBD
T2Management Change
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▼Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-06-28 | Paragard T 380a (copper) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-06-28 | Paragard T 380a (copper) | PDUFA Date | PDUFA | Approved | – | – | – |
2024-06-28 | Paragard T 380a (copper) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
C49
Pipeline Score $1.8B
Pipeline ValueValuation Signal
9
Drugs Scored0.5x
rNPV / MCap Top 77%
Mid Cap (rank 211 of 913)
Percentile RankThe Cooper Companies, Inc. carries a moderate pipeline score (49/100), with $2.1B risk-adjusted pipeline value, led by Normal saline ,Control in Migraine Headache (Phase 3), across $91B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal saline ,Control Unknown | Migraine Headache | Phase 3 | NCT02933060 | 46% | $744M | COMPLETED | 50 | - | - | Sep 1, 2017 | - | Jul 15, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COOCooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure
CooperCompanies has released its 2025 Corporate Sustainability Report, highlighting its commitment to sustainability through the disclosure of Scope 3 greenhouse gas emissions. The report details innovations in vision care and women's health, including the MADE BETTER™ platform and new reproductive health solutions. The company aligns with major sustainability frameworks, showcasing its dedication to responsible practices.
Read more →COOCooperCompanies Announces Second Quarter 2026 Results
CooperCompanies reported strong financial results for Q2 2026, with revenues reaching $1.082 billion, an 8% increase from the previous year. Non-GAAP diluted EPS rose to $1.21, up 26% year-over-year. However, GAAP EPS fell to $(0.40) due to a significant litigation charge related to a product recall. The company also resolved most claims associated with the recall, allowing for a strategic review moving forward.
Read more →COOCooperCompanies Appoints Paul Keel to its Board of Directors
CooperCompanies has appointed Paul Keel as an independent director, effective July 1, 2026. Keel brings extensive experience from his roles at Envista Holdings and Smiths Group, which will be valuable for the company's strategic execution. He will also serve on the Audit Committee, further enhancing the Board's capabilities.
Read more →COOCooperCompanies Announces Release Date for Second Quarter 2026
CooperCompanies has announced that it will release its financial results for the second quarter of 2026 on June 4, 2026. Following the announcement, a conference call will be held to discuss the results and corporate developments. Interested parties can join the call using the provided dial-in number and access the webcast online.
Read more →COOCooperVision Launches MiSight® 1 day in Japan; Becomes First Myopia Control Contact Lens in Leading Vision Care Market
CooperVision has launched its MiSight® 1 day myopia control contact lens in Japan, marking a significant advancement in myopia management for children. This lens is the first of its kind authorized by Japan's Ministry of Health for myopia correction and progression control. With a high prevalence of myopia among Japanese children, this launch aims to improve their vision and quality of life.
Read more →COOCooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
CooperCompanies has appointed Walter M Rosebrough, Jr. as an independent director, effective January 3, 2026. This appointment is part of a cooperation agreement with Browning West, which aims to enhance the board's effectiveness. Rosebrough's extensive experience in the medical device sector is expected to contribute to the company's strategic vision and shareholder value.
Read more →COOCooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors Enters into Cooperation Agreement with Browning West
CooperCompanies has appointed Walter M. Rosebrough, Jr. as an independent director, effective January 3, 2026, as part of a cooperation agreement with Browning West. Rosebrough, who has extensive experience in the medical device industry, is expected to contribute to the company's strategic vision and shareholder value. The agreement includes plans for additional board refreshment, demonstrating a commitment to unlocking sustained value. Browning West will support the current board slate at the 2026 Annual Meeting of Stockholders.
Read more →COOCooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025
CooperCompanies has announced the release date for its fourth quarter and full year 2025 financial results, scheduled for December 4, 2025. The company will host a conference call at 5:00 PM ET to discuss these results and other corporate developments. Interested parties can join the call using the provided dial-in number and conference ID.
Read more →COOCooperCompanies Announces Expanded Share Repurchase Program
CooperCompanies has announced a $1 billion increase to its share repurchase program, bringing the total to $2 billion. This decision reflects the company's strong balance sheet and commitment to returning capital to shareholders. The timing and amount of repurchases will depend on market conditions, and the program has no termination date.
Read more →COO▼ -12.9%on this news
CooperCompanies Announces Third Quarter 2025 Results
CooperCompanies announced its fiscal third quarter results, highlighting strong margins and double-digit earnings growth despite revenues falling short of expectations. CEO Al White expressed confidence in the company's operational performance and raised earnings guidance for the upcoming quarter. The company anticipates improved revenue driven by its MyDAY® product line in fiscal 2026.
Read more →COOCooperCompanies to Participate in the Wells Fargo Healthcare Conference
CooperCompanies will participate in the Wells Fargo Healthcare Conference on September 3, 2025. Al White, the President and CEO, will represent the company during the session. The event will be available via webcast for investors and interested parties. CooperCompanies is known for its contributions to the medical device sector, particularly in vision and women's healthcare.
Read more →COOCooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet
CooperCompanies has released its 2024 Sustainability Report, highlighting its commitment to sustainability and positive impact on society and the environment. The report details partnerships aimed at reducing plastic use, certifications achieved, and investments in employee development. It aligns with the Sustainability Accounting Standards Board standards, emphasizing the company's dedication to responsible practices.
Read more →COOCooperCompanies to Participate in the William Blair Growth Stock Conference
CooperCompanies will participate in the William Blair Growth Stock Conference on June 5, 2025. Brian Andrews, the CFO, will represent the company during the session. The event will be accessible via a webcast for investors and interested parties, showcasing CooperCompanies' ongoing commitment to investor engagement.
Read more →COOCooperCompanies Appoints Barbara Carbone to Board of Directors
CooperCompanies has appointed Barbara Carbone as an independent director, effective May 1, 2025. Carbone, who has nearly four decades of experience, will also serve on the Audit Committee. Her background includes significant roles at KPMG LLP, where she was an Audit Partner for over 24 years. The Chairman of the Board expressed excitement about her contributions to the company.
Read more →COOCooperCompanies Appoints Cynthia Lucchese to Board of Directors
CooperCompanies Appoints Cynthia Lucchese to Board of Directors SAN RAMON, Calif., October 3, 2022 - CooperCompanies (NYSE: COO) announced today that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022. Lucchese has also b
Read more →COOCooperCompanies to Acquire Cook Medical s Reproductive Health Business Acquisition will enhance CooperSurgical s international fertility footprint and medical device portfolio.
CooperCompanies to Acquire Cook Medical s Reproductive Health Business Acquisition will enhance CooperSurgical s international fertility footprint and medical device portfolio. SAN RAMON, Calif., February 7, 2022 CooperCompanies (NYSE: COO) today announced it has signed a bind
Read more →COOCooperCompanies Completes Acquisition of Generate Life Sciences
CooperCompanies Completes Acquisition of Generate Life Sciences SAN RAMON, Calif., December 17, 2021 CooperCompanies (NYSE: COO) today announced it has completed the previously announced definitive purchase agreement to acquire Generate Life Sciences, a leading provider of dono
Read more →COOCooperCompanies to Acquire Generate Life Sciences for $1.6 Billion Acquisition will Expand CooperSurgical s Fertility and Labor & Delivery Offerings
CooperCompanies to Acquire Generate Life Sciences for $1.6 Billion Acquisition will Expand CooperSurgical s Fertility and Labor & Delivery Offerings SAN RAMON, Calif., November 10, 2021 CooperCompanies (NYSE: COO) today announced that it has signed a definitive purchase agre
Read more →COOCooperCompanies Elects Maria Rivas, MD to Board of Directors
CooperCompanies Elects Maria Rivas, MD to Board of Directors SAN RAMON, Calif., May 12, 2021 CooperCompanies (NYSE: COO) announced today that its Board of Directors has elected Dr. Maria Rivas as an independent director, effective July 1, 2021. We are pleased to welcome Maria
Read more →COOA. Thomas Bender and Allan E. Rubenstein, M.D. to Retire from CooperCompanies Board
A. Thomas Bender and Allan E. Rubenstein, M.D. to Retire from CooperCompanies Board Calif., December 10, 2020 CooperCompanies (NYSE:COO) announced today that A. Thomas Bender and Allan E. Rubenstein, M.D. have decided to retire and will not stand for re-election at the Annual
Read more →COOCooperCompanies Elects Teresa S. Madden to Board of Directors
CooperCompanies Elects Teresa S. Madden to Board of Directors SAN RAMON, Calif., November 12, 2020 CooperCompanies (NYSE: COO) announced today that its Board of Directors elected Teresa S. Madden to the Board as an independent director, effective December 1, 2020. We are delig
Read more →COOCooperCompanies Appoints Holly Sheffield as President, CooperSurgical and Announces Robert Auerbach, M.D. to Retire
CooperCompanies Appoints Holly Sheffield as President, CooperSurgical and Announces Robert Auerbach, M.D. to Retire SAN RAMON, Calif., July 6, 2020 CooperCompanies (NYSE:COO) today announced that Holly Sheffield has been appointed President of CooperSurgical effective July 13,
Read more →COOCooperCompanies Announces $2.14 Billion Senior Credit Facility and Amendment of $500 Million 364-Day Credit Facility
CooperCompanies Announces $2.14 Billion Senior Credit Facility and Amendment of $500 Million 364-Day Credit Facility SAN RAMON, Calif., April 1, 2020 - CooperCompanies (NYSE:COO) today announced the closing of a new five-year $2.14 billion senior unsecured credit facility, compr
Read more →COOKim Duncan Vice President, Investor Relations The Cooper Companies, Inc. ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com
BRIAN ANDREWS TO SUCCEED ALBERT WHITE AS CHIEF FINANCIAL OFFICER OF THE COOPER COMPANIES PLEASANTON, Calif., April 23, 2018 The Cooper Companies, Inc. (NYSE: COO) today announced that Brian Andrews has been promoted to Senior Vice President, Chief Financial Officer and Treasur
Read more →COOobligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reason
NEWS RELEASE 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER RESULTS PLEASANTON, Calif., March 2, 2017 - The Cooper Comp
Read more →COOKim Duncan Vice President, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES FOURTH QUARTER AN
NEWS RELEASE CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2016 RESULTS PLEASANTON, Calif., December
Read more →COOStoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com NEWS RELEASE CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com
6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com NEWS RELEASE CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com THE COOPER COMPANIES ACQUIRES WALLACE FROM SMITHS MEDICAL PLEASANTON, Calif., November 6, 2016 The Coo
Read more →COOKim Duncan Vice President, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES CFO GREGORY W. MATZ TO RETI
NEWS RELEASE CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES CFO GREGORY W. MATZ TO RETIRE; ALBERT G. WHITE NAMED SUCCESSOR IN PLANNED TRANSITI
Read more →COOKim Duncan Vice President, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES SECOND QUARTER 20
THE COOPER COMPANIES ANNOUNCES SECOND QUARTER 2016 RESULTS PLEASANTON, Calif., June 2, 2016 The Cooper Companies, Inc. (NYSE: COO) today announced financial results for the fiscal second quarter ended April 30, 2016. Commenting on the results, Robert S. Weiss, Cooper s preside
Read more →COO6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com
NEWS RELEASE 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com THE COOPER COMPANIES APPOINTS WILLIAM KOZY AND COLLEEN JAY TO BOARD OF DIRECTORS PLEASANTON, Calif., Apr
Read more →COO6140 Stoneridge Mall Road CONTACT: Suite 590 Kim Duncan Pleasanton, CA 94588 Vice President, Investor Relations 925-460-3663 ir@cooperco.com www.coopercos.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER 201
NEWS RELEASE 6140 Stoneridge Mall Road CONTACT: Suite 590 Kim Duncan Pleasanton, CA 94588 Vice President, Investor Relations 925-460-3663 ir@cooperco.com www.coopercos.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER 2016 RESULTS PLEASANTON, Calif., March 3, 2016 The Co
Read more →COO6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com THE COOPER COMPANIES ANNOUNCES THIRD QUARTER 201
NEWS RELEASE 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com THE COOPER COMPANIES ANNOUNCES THIRD QUARTER 2015 RESULTS PLEASANTON, Calif., September 3, 2015 The Coop
Read more →COO6140 Stoneridge Mall Road CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES SECOND QUARTER 20
NEWS RELEASE 6140 Stoneridge Mall Road CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES SECOND QUARTER 2015 RESULTS PLEASANTON, Calif., June 4, 2015 The Coope
Read more →COOKim Duncan Vice President, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER 201
NEWS RELEASE CONTACT: Kim Duncan Vice President, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER 2015 RESULTS PLEASANTON, Calif., March 5, 2015 The Cooper
Read more →COOKim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES THIRD QUARTER 20
THE COOPER COMPANIES ANNOUNCES THIRD QUARTER 2014 RESULTS PLEASANTON, Calif., September 4, 2014 The Cooper Companies, Inc. (NYSE: COO) today announced financial results for the fiscal third quarter ended July 31, 2014. Commenting on the results, Robert S. Weiss, Cooper s presi
Read more →COO6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Senior Director, Investor Relations ir@cooperco.com THE COOPER COMPANIES COMPLETES ACQUISITION OF S
NEWS RELEASE 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Senior Director, Investor Relations ir@cooperco.com THE COOPER COMPANIES COMPLETES ACQUISITION OF SAUFLON PHARMACEUTICALS AND ANNOUNCES $700 MILLION 3-YEAR
Read more →COO6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Senior Director, Investor Relations ir@cooperco.com
NEWS RELEASE 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com CONTACT: Kim Duncan Senior Director, Investor Relations ir@cooperco.com THE COOPER COMPANIES ANNOUNCES DEFINITIVE AGREEMENTS TO ACQUIRE SAUFLON PHARMACEUTICALS LTD PLEASANTON
Read more →COOKim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES SECOND QUARTER 2
NEWS RELEASE CONTACT: Kim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES SECOND QUARTER 2014 RESULTS PLEASANTON, Calif., June 5, 2014 The Cooper
Read more →COOKim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER 20
NEWS RELEASE CONTACT: Kim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER 2014 RESULTS PLEASANTON, Calif., March 6, 2014 The Cooper
Read more →COOKim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com
NEWS RELEASE CONTACT: Kim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES EXPANDS SHARE REPURCHASE PROGRAM PLEASANTON, Calif., December 12, 2013 The Co
Read more →COOKim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES FOURTH QUARTER A
NEWS RELEASE CONTACT: Kim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com THE COOPER COMPANIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2013 RESULTS PLEASANTON, Calif., December
Read more →COO6140 Stoneridge Mall Road CONTACT: Suite 590 Pleasanton, CA 94588 Kim Duncan 925-460-3663 Senior Director, Investor Relations www.coopercos.com The Cooper Companies, Inc. ir@cooperco.com THE COOPER COMPANIES
NEWS RELEASE 6140 Stoneridge Mall Road CONTACT: Suite 590 Pleasanton, CA 94588 Kim Duncan 925-460-3663 Senior Director, Investor Relations www.coopercos.com The Cooper Companies, Inc. ir@cooperco.com THE COOPER COMPANIES ANNOUNCES $300 MILLION 5-YEAR TERM LOAN PLEASA
Read more →COO6140 Stoneridge Mall Road CONTACT: Suite 590 Kim Duncan Pleasanton, CA 94588 Senior Director, Investor Relations 925-460-3663 ir@cooperco.com www.coopercos.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER 20
NEWS RELEASE 6140 Stoneridge Mall Road CONTACT: Suite 590 Kim Duncan Pleasanton, CA 94588 Senior Director, Investor Relations 925-460-3663 ir@cooperco.com www.coopercos.com THE COOPER COMPANIES ANNOUNCES FIRST QUARTER 2013 RESULTS PLEASANTON, Calif., March 7, 2013 The C
Read more →Competitive Position
How COO ranks across every disease it competes inCompetitive Position is a premium feature
See how COO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial